NCT02416453View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

423

Participants

Timeline

Start Date

June 15, 2015

Primary Completion Date

January 19, 2018

Study Completion Date

January 19, 2018

Conditions

Ebola Viral Disease

Interventions

BIOLOGICAL

MVA-BN-Filo

One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.

BIOLOGICAL

Ad26.ZEBOV

One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.

BIOLOGICAL

Placebo

One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.

Trial Locations (11)

Unknown

Créteil

Marseille

Paris

Pierre-Bénite

Rennes

Saint-Etienne

Strasbourg

Tours

London

Oxford

Southampton

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

University of Oxford

OTHER

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT02416453 - A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults | Biotech Hunter | Biotech Hunter